m6A修饰调控RP11-426A6.5在喉鳞状细胞癌中的作用与机制
该研究收集2017年1月至9月哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科48例喉鳞状细胞癌患者的癌及癌旁组织,通过芯片、MeRIP-qPCR和qRT-PCR检测RP11-426A6.5的m6A修饰与表达,并结合体外RNA干扰及裸鼠成瘤实验探讨其功能。结果显示癌组织RP11-426A6.5甲基化及表达水平高于癌旁组织,高表达患者术后生存期较低表达组短,下调RP11-426A6.5可抑制LSCC细胞增殖、迁移、侵袭及移植瘤生长,METTL3参与其m6A修饰调控。
要点
- LSCC癌组织RP11-426A6.5甲基化及表达水平均高于癌旁组织(P值均<0.05)。
- RP11-426A6.5表达与T分期相关,T3-4期高于T1-2期(χ2=5.35,P<0.05)。
- 高表达RP11-426A6.5患者术后生存期低于低表达组(P=0.046)。
核心结论
- RP11-426A6.5能够调控LSCC细胞的恶性行为,并受到甲基转移酶METTL3所参与的m6A修饰过程调控。
研究设计与样本
- 收集2017年1月至9月哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科收治的48例LSCC患者癌及癌旁组织,选取其中3例样本行lncRNA m6A甲基化芯片及表达谱芯片检测。
- 在其余45例LSCC样本中通过MeRIP-qPCR及qRT-PCR验证RP11-426A6.5的m6A修饰和表达水平,并分析其与临床因素的相关性。
- 体外运用RNAi技术构建低表达RP11-426A6.5喉癌细胞系,以EdU增殖实验、伤口愈合实验、Transwell侵袭实验观察细胞增殖、迁移、侵袭变化。
- 以裸鼠成瘤实验验证RP11-426A6.5下调后对体内移植瘤生长的影响。
- 应用TCGA数据库及SRAMP网站预测介导RP11-426A6.5 m6A修饰的相关酶及甲基化位点,选用MazF酶切法验证结合位点;以RNAi干扰修饰酶相应基因后观察细胞功能改变并用MeRIP-qPCR检测RP11-426A6.5 m6A水平,以放射线菌素D处理细胞系观察RP11-426A6.5稳定性改变。
主要发现
- LSCC组织RP11-426A6.5甲基化水平为23.828±4.975,高于癌旁组织的20.280±3.607,P<0.05。
- LSCC组织RP11-426A6.5表达水平为1.197±0.314,高于癌旁组织的1.015±0.170,P<0.05。
- RP11-426A6.5表达水平与T分期相关:T1-2期为1.081±0.298,T3-4期为1.306±0.292,χ2=5.35,P<0.05。
- RP11-426A6.5高表达患者术后生存期明显低于低表达组患者,差异有统计学意义(P=0.046)。
- 体内外试验显示下调RP11-426A6.5后LSCC细胞增殖、迁移、侵袭能力显著下降,移植瘤生长受到明显抑制。
关键数值与推荐
- m6A修饰酶甲基化转移酶样蛋白3(METTL3)与RP11-426A6.5相应甲基化位点结合增强其稳定性,并介导其对LSCC细胞恶性行为的调控。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the roles of N6-methyladenosine (m6A) modification in regulating RP11-426A6.5 in the development of laryngeal squamous cell carcinoma (LSCC). Methods: The methylation and expression levels of lncRNAs were identified and important lncRNAs were screened utilizing long non-coding RNA (lncRNA) m6A methylation microarray. Cancer and para cancer tissue samples were taken from 48 LSCC patients hospitalized to the Department of Otolaryngology-Head and Neck Surgery of the Second Affiliated Hospital of Harbin Medical University between January and September 2017. Expression profiling microarray was performed in 3 of 48 LSCC samples, and methylated RNA immunoprecipitation-quantitative PCR (MeRIP-qPCR) and quantitative real-time fluorescent PCR (qRT-PCR) were performed in the remaining 45 LSCC samples to verify the m6A modification and expression levels of RP11-426A6.5. Correlations between RP11-426A6.5 and clinical factors were anlysed. Laryngeal cancer cell line with low expression of RP11-426A6.5 was created in vitro using RNA interference (RNAi) technology. The 5-Ethynyl-2'-deoxyuridine (EdU) cell proliferation experiment, wound healing experiment, and transwell invasion experiment were used respectively to measure the proliferation, migration, and invasion of LSCC cells. The effect of RP11-426A6.5 down-regulation on the growth of transplanted tumors in vivo was verified by nude mice tumorigenesis assay. The Cancer Genome Atlas (TCGA) database and sequence-based RNA adenosine methylation site predictor (SRAMP) website were used to predict the enzymes and corresponding methylation sites. MazF digestion was chosen to validate the binding sites. RNAi technology was used to observe the changes in cell function after interfering with the expression of the corresponding genes of the modified enzymes. MeRIP-qPCR was used to detect the level of RP11-426A6.5 m6A cell line treated with actinomycin D was used to observe the stability of RP11-426A6.5. Results: RP11-426A6.5 methylation and expression levels were significantly higher in LSCC tissues than those in paracancerous tissues (methylation levels: 23.828±4.975 vs 20.280±3.607; expression levels: 1.197±0.314 vs 1.015±0.170, all P values<0.05). RP11-426A6.5 expression levels were closely correlated with T stage (T1-2: 1.081±0.298 vs T3-4: 1.306±0.292, χ2=5.35, P<0.05). The postoperative survival of patients with high RP11-426A6.5 expressions was significantly lower than that of patients with low RP11-426A6.5 expression (P=0.046). Assays in vitro and in vivo showed that the downregulation of RP11-426A6.5 significantly decreased the proliferation, migration, and invasion abilities of LSCC cells and the growth of transplanted tumors. The binding of methyltransferase-like 3 (METTL3), an m6A-modified enzyme, to the corresponding methylation site of RP11-426A6.5 enhanced its stability and mediated its regulation of malignant behaviors of LSCC cells. Conclusions: RP11-426A6.5 can regulate the malignant behaviors of LSCC cells, which is mediated by the m6A modification process involving in the methyltransferase METTL3. 目的: 探究N6-甲基腺苷(N6-methyladenosine,m6A)修饰调控RP11-426A6.5在喉鳞状细胞癌(laryngeal squamous cell carcinoma,LSCC)发生与发展过程中的作用机制。 方法: 收集2017年1月至9月哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科收治的48例LSCC患者的癌及癌旁组织,选取其中3例LSCC样本利用长链非编码RNA(long non-coding RNA,lncRNA)m6A甲基化芯片及表达谱芯片技术检测lncRNAs的甲基化和表达水平并筛选关键lncRNA。通过甲基化RNA免疫共沉淀-定量PCR(methylated RNA immunoprecipitation-quantitative PCR,MeRIP-qPCR)及实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)在其余45例LSCC样本中验证RP11-426A6.5的m6A修饰和表达水平,并分析RP11-426A6.5与肿瘤恶性程度、预后等临床因素间的相关性。在体外,运用RNA干扰(RNA interference,RNAi)技术构建低表达RP11-426A6.5喉癌细胞系,以EdU细胞增殖检测实验、伤口愈合实验、Transwell侵袭实验分别观察LSCC细胞的增殖、迁移、侵袭等生物学功能变化,以裸鼠成瘤实验验证RP11-426A6.5下调后对体内移植瘤生长的影响。应用TCGA数据库及SRAMP网站预测介导RP11-426A6.5 m6A修饰的相关酶及相应甲基化位点,选用MazF酶切法对结合位点验证。运用RNAi技术在细胞水平干扰修饰酶相应基因表达后观察细胞功能的改变并利用MeRIP-qPCR检测RP11-426A6.5 m6A水平变化,以放射线菌素D处理细胞系观察RP11-426A6.5稳定性改变。 结果: LSCC组织中RP11-426A6.5甲基化及表达水平明显高于癌旁组织[RP11-426A6.5甲基化水平:癌组织(23.828±4.975)比癌旁组织(20.280±3.607),RP11-426A6.5表达水平:癌组织(1.197±0.314)比癌旁组织(1.015±0.170),P值均<0.05],且RP11-426A6.5表达水平与肿瘤大小(T期)密切相关[T1-2期(1.081±0.298)比T3-4期(1.306±0.292),χ2=5.35,P<0.05]。RP11-426A6.5高表达患者的术后生存期明显低于低表达组患者,差异有统计学意义(P=0.046)。体内外试验结果显示下调RP11-426A6.5后LSCC细胞增殖、迁移、侵袭能力显著下降且移植瘤生长受到明显抑制。m6A修饰酶中甲基化转移酶样蛋白3(methyltransferase-like 3,METTL3)与RP11-426A6.5相应甲基化位点结合增强其稳定性并介导其对LSCC细胞恶性行为的调控。 结论: RP11-426A6.5能够调控LSCC细胞的恶性行为并受到甲基转移酶METTL3所参与的m6A修饰过程调控。.
引用
- Yan BR, Wang P, Li YS, et al. [Roles and mechanisms of m6A modification regulating RP11-426A6.5 in laryngeal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022. PMID: 36707952. doi:10.3760/cma.j.cn115330-20220313-00111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。